ER + HER2- breast cancer with HG III features shows more aggressive clinical behavior than HG I/II tumors, characterized by larger tumor size, higher nodal involvement, and increased proliferative index, which correlate with worse prognosis and the need for more intensive therapy [31–33]. The gene discussed is ERBB2; the disease is neoplasm.